M
Mereo BioPharma Group plc (MREO)
NCM – Real vaqt narxi. Valyuta: USD
0.25
+0.00 (1.44%)
Yopilishda: May 12, 2026, 4:00 PM EDT
0.25
0.00 (0.00%)
Bozor oldidan: May 13, 2026, 4:57 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.25
+0.00 (1.44%)
Yopilishda: May 12, 2026, 4:00 PM EDT
0.25
0.00 (0.00%)
Bozor oldidan: May 13, 2026, 4:57 AM EDT
Mereo BioPharma Group plc, biofarmatsevtika kompaniyasi, Buyuk Britaniya va AQShda kam uchraydigan kasalliklarni davolash uchun terapevtik vositalarni ishlab chiqadi va tijoratlashtiradi. Kompaniya osteogenez imperfecta (suyak sinuvchanligi kasalligi)ni davolash uchun antitel bo'lgan Setrusumabni; alfa-1-antitripsin tanqisligi bilan bog'liq o'pka kasalligini davolash uchun II bosqich klinik sinovlarida bo'lgan og'iz orqali qabul qilinadigan kichik molekula Alvelestatni; va autosomal dominant osteopetroz tip 2ni davolash uchun anti-FZD monoklonal antitel Vantictumabni ishlab chiqadi. Shuningdek, u gipogonadotrop gipogonadizmni davolashda qo'llash uchun 2-bosqich sinovlarida bo'lgan og'iz orqali qabul qilinadigan aromataza ingibitori Leflutrozolni; tuxumdon saratoni oxirgi bosqichlarini davolash uchun 1b bosqich klinik sinovlarini yakunlagan Navicixizumabni; keng tarqalgan qattiq o'smalarni davolash uchun immunitet hujayralaridagi inson TIGIT retseptoriga bog'lanadigan IgG1 monoklonal antitel Etigilimabni; va surunkali obstruktiv o'pka kasalligining o'tkir zo'rayishlarini davolash uchun II bosqich klinik sinovlarida bo'lgan p38 MAP kinaza ingibitori Acumapimodni ishlab chiqadi. Kompaniya navicixizumabni ishlab chiqish va tijoratlashtirish bo'yicha Feng Biosciences bilan; leflutrozolni ishlab chiqish va tijoratlashtirish bo'yicha ReproNovo bilan litsenzion shartnomalarga ega; va AstraZeneca bilan litsenziyalash shartnomasiga ega. Mereo BioPharma Group plc 2015 yilda tashkil etilgan va uning shtab-kvartirasi London, Buyuk Britaniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Denise Vera Scots-Knight Ph.D. | Co-Founder, CEO & Executive Director |
| Dr. Jackie Parkin | Senior VP & Therapeutic Head |
| Dr. John A. Lewicki Ph.D. | Chief Scientific Officer |
| Dr. Ogun Sazova | VP & Head of Medical Affairs |
| Mr. Bo Kara | Senior VP and Head of Pharmaceutical Development & CMC |
| Mr. Charles Edward Sermon | Co-Founder, General Counsel, Business Development & Company Secretary |
| Ms. Alexandra Hughes-Wilson | Chief of Patient Access & Commercial Planning |
| Ms. Bal Lally | VP & Head of HR |
| Ms. Bharti Navsariwala | VP & Head of Regulatory Affairs |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-09 | DEF 14A | mreo-20260407.htm |
| 2026-04-09 | ARS | mreo_2025_ars_filed.pdf |
| 2026-03-27 | PRE 14A | mreo-20260327.htm |
| 2026-03-19 | 8-K | mreo-20260319.htm |
| 2026-03-19 | 10-K | mreo-20251231.htm |
| 2026-02-17 | 8-K | mreo-20260217.htm |
| 2026-02-02 | S-8 | mreo-20260202.htm |
| 2026-01-12 | 8-K | mreo-20260112.htm |
| 2025-12-29 | 8-K | mreo-20251229.htm |
| 2025-11-10 | 8-K | mreo-20251110.htm |